Hi Cody, Thanks a lot for your reasonable response to my

New Post Public Reply Private Reply Replies (1) Message Board
Zolis_onkel Cody760 #34281
540
Hi Cody,

Thanks a lot for your reasonable response to my post. I am happy to discuss these matters on that basis, which is very different from these "the sky is falling" (a judgement mostly based on negative speculation) posts that I am shaking my head about.
So here is my reply to your post.
1) for sure the situation does not look good, but only because we do not know what is really going on and we do not receive any first hand information from the company officials directly. Agreed.
2) Why do you think that they have been running out of money? If they would have, they would have been giving out shares to keep the lights on, as they did in the summer and fall months. And in case there is no investigation, as some here strongly suggest, what keeps them from doing so? Fact is they don't. This is a fact, because the official otcmarkets website says so.
3) Now why are they not diluting the heck out of the stock? Three possible answers come to my mind:
a) they are actually generating enough revenue from the Excellegen sales, which they had laid out clear plans for during the last CC in May. Capital was about to be secured through debt financing and the strategy was very clearly described. If they have only been 50% successful with the described roll out, as planned, there should millions be rolling in by now every month.
b) they are not allowed to give out new shares due to an investigation that is going on, which restricts them also in communication to the public/us shareholders. This scenario is also supported by the fact that Joe gave hints to some posters and the canned emails some received from Todd, where he said that they are still making progress and all fronts, but he is not able to talk about details right now. How long this will still be so he can't really predict. In addition, based on all of our personal experiences with the company, it is very unusual that they remain in CompleteSilence for such a long time, and thus it is hard for me to believe that they are doing this for any other reason than a gag order.
Question remains if the lack of funding is really limiting them, or do they come along well without additional funding, e.g. due to a)
c) as you suggested, they ran into problems, simply gave up and all just left. I honestly doubt that Joe would do something like that, especially after he had dedicated almost 5 years of his life on this already. And even if that is true, would he actually still be posting trash about other vaccine developers and their products? If I world have given up on such an endeavor, I would not be bothered with this at all anymore, but minding my own business and trying to figure out what to do next in my life. Don't you agree?
4) I do agree with you on your suggestion that Joe and his team "have been overtaken by events beyond their control". I recently read a longer article about the reasons why this pandemic had to happen to save the world's financial systems. Now, of course, this very much sounds like a conspiracy theory, but it was very well written (in German, which is why I am not providing a link here, but whomever is interested, can send me private message and I will send it), and most of the allegations made, were proven via links to official governmental websites, etc. So I can absolutely believe this to be true.

In this described conspiracy it is necessary that a) a vaccine is used that causes a lot of side effects (all of a sudden the choice of that mRNA technology makes sense) and even deaths, and b) that a vast majority of people in western countries are vaccinated (so ever since it is clear to me that our governments will sooner or later make a vaccination mandatory).
Assuming this to be true, the "deep state" conspirists cannot use a CompleteVaccine that has very little side effects and provides long term immunity, which is why GNBT has never received funding from BARDA and a quick refusal from that other "Bill Gates foundation" organization, who clearly stated that they would only support mRNA vaccine developments. After that and Joe's decision to continue anyways, they faced one problem after the next, the FDA requested yet another and another set of tests, in the meantime the pps was being manipulated down and now the company is under investigation for the most part of the last two years. First a deep dive review of their 2019 10-k and now something else.
I know, I know how this sounds, and I am not saying that this is true, but connecting the dots this way, a lot questions (eg. Why has BARDA funded almost solely the development of mRNA vaccine developments, which entirely defies any of my common sense or logic) for me receive answers.

And no, this has nothing to do with defending Joe, or trying to give him an easy way out or absolution. The "bad actors" he has been referring to and used as excuses for his short comings, are still mostly his fault and due to his naivity or lack of proper due diligence etc.

OK, enough said, now hit me with your responses. Hard had and coat of mail are on already. LOL

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MAMMOTION's Bold Leap in Robotic Lawn Care at IFA 2026

Updated Category News Views 3

MAMMOTION Makes Waves with New Robotic Mowers Gather 'round, folks, because MAMMOTION's making some noise over at IFA 2026 in Berlin. If you've been stuck battling the wild edges of your lawn with a rusty old mower, MAMMOTION might just have the tech to save your weekends—and some grass along the way. This ain't no shiny gadget; it’s a full-on upgrade to lawn war...

Continue Reading
Holland America Evolution: Revamping Luxury at Sea

Updated Category News Views 3

Setting Sail on a Fresh Wave of Luxury It's a whole new world aboard the Oosterdam, folks. Holland America's making waves with the debut of a reimagined Ocean Bar that promises to inject a healthy dose of glamour back into cruising. Forget the stuffy maritime tales of yesteryear; this isn't just a facelift—it's a full-blown Renaissance at sea. A nod to the golden age of...

Continue Reading
Beyoncé Drops Remastered 'B'DAY'; Celebrates Legacy

Updated Category News Views 2

Every so often, an artist comes around who's not just making music but shifting the very landscape of their genre. Beyoncé isn't just marking her birthday today; she's reminding the world of a career-defining moment with the release of her remastered deluxe version of 'B'DAY'. This isn't just a stroll down memory lane; it's a full-blown revival of an era that reshaped...

Continue Reading
Eosera Defies Odds with Texas-Made Ear Care Dominance

Updated Category News Views 3

Who would've thought an ear care outfit outta Fort Worth could snag a spot on the Inc. 5000 list for six years running? That's right, eosera® is hanging tough, even while the industry's been in a tailspin and tariffs have been squeezing everyone’s margins. Pushing Through Tough Terrain The ear care sector isn't exactly the first place investors look for a splash,...

Continue Reading
Aardvark Therapeutics Faces Investor Lawsuit for Fraud

Updated Category News Views 1

Investors' Trust on Shaky Grounds There it is, staring right back at investors: a securities fraud class action lawsuit against Aardvark Therapeutics. Not exactly the news a shareholder wants to digest over breakfast. If you’ve got skin in the game with Aardvark Therapeutics (NASDAQ: AARD), you might wanna keep reading. Hagens Berman Sobol Shapiro LLP, a name that's no...

Continue Reading
Hamamatsu & AIxMed to Automate Cytology Workflows

Updated Category News Views 2

Why This Collaboration Matters Here comes an interesting tidbit from the world of cytology: Hamamatsu and AIxMed are banding together to tackle workflow inefficiencies. Picture this—two powerhouses coming together to create a tool that might just relieve lab technicians from the tedious task of manually checking cytology slides. In a world where efficiency is king, this...

Continue Reading
Aristocrat's Tiki Fire Slots Heat Up North America

Updated Category News Views 0

The Polynesian Flame Ignites: Tiki Fire Hits Online Games Just when you thought the iGaming world was catching its breath, Aristocrat Interactive throws another curveball. The buzz around their Lightning Link™ series, especially the launch of High Stakes™ in July, took the scene by storm. Now, just in time for another sizzle, they've rolled out Tiki Fire™, bringing...

Continue Reading
USSM and IonicRE Partner to Enhance US Rare Earths Supply

Updated Category News Views 1

Sometimes, it's not just about playing the game, but knowing which card to play. US Strategic Metals (USSM) and Ionic Rare Earths USA just unveiled a strategic move that’s likely to shake things up in the wild world of rare earths. As the partnership gears up to build a magnet recycling facility in Missouri, there’s chatter around creating a sustainable supply chain...

Continue Reading
Wise Group Investors Alert Ahead of Key Legal Deadline

Updated Category News Views 0

Sizing Up the Legal Stakes for Wise Group Alright, here's a doozy that's bound to get your attention if you've got a stake in Wise Group plc (NASDAQ: WSE). We're talking about a looming securities class action, with the deadline to get involved barreling down like a runaway freight train. Before September 29, 2026, to be exact—mark it, circle it, do whatever you have to...

Continue Reading
Curaleaf Eyes Growth: Conference Signals Opportunities

Updated Category News Views 1

Curaleaf's Strategic Move: Getting in Front of Investors Here comes Curaleaf Holdings, stepping into the spotlight with their eye on increasing investor engagement. Announcing their participation in the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference, the folks at Curaleaf aren't just talking—they're putting their top brass under the lights. You...

Continue Reading

Top 5 Most Recently Viewed Articles

Beazer Homes Boosts Share Repurchase Campaign Amid Market Changes

Updated Category News Views 95

Beazer Homes Increases Share Repurchase Initiative Beazer Homes USA, Inc. (NYSE: BZH) has recently communicated a significant acceleration in its share repurchase activity, a move prompted by fluctuations in its share price. The company has approximately $24.8 million remaining under its authorized share repurchase program. This decision illustrates Beazer's commitment to...

Continue Reading
Takeda Shares Groundbreaking Findings on Narcolepsy Treatment

Updated Category News Views 94

Groundbreaking Narcolepsy Treatment Insights by Takeda In a major development for those living with narcolepsy, Takeda will share important findings about its innovative drug, TAK-861, at Sleep Europe 2024. This conference is a key moment for Takeda to highlight progress in both understanding and treating this complex condition. Narcolepsy typically presents as...

Continue Reading
Celebrate Presidents Day with the U.S. Postal Service Updates

Updated Category News Views 151

Understanding Presidents Day Observance by the U.S. Postal Service The U.S. Postal Service (USPS) recognizes Presidents Day as a holiday, meaning that all Post Office locations will be closed, providing a day of rest for employees while encouraging customers to utilize self-service options. This aligns with the USPS commitment to serving communities effectively. Accessing...

Continue Reading
Sidetrade Celebrates Major Milestone in Euronext Tech Leaders

Updated Category News Views 180

Sidetrade's Prominent Inclusion in Euronext's Tech Leaders Sidetrade, a frontrunner in AI-driven Order-to-Cash applications, recently announced its inclusion in the prestigious Euronext Tech Leaders Index, a pan-European initiative that highlights the continent’s most innovative and rapidly growing tech companies. This initiative, launched in 2022 by Euronext,...

Continue Reading
Cue Biopharma Sees Promising Growth in Recent Financial Review

Updated Category News Views 125

Cue Biopharma's Financial Highlights and Strategic Changes BOSTON — Cue Biopharma, Inc. (NASDAQ: CUE), a trailblazer in the biopharmaceutical sector, is focused on revolutionizing immunotherapy through its innovative therapies. The company has reported substantial progress in its fourth quarter and full year 2024 financial results, underscoring its commitment to...

Continue Reading